GRTX — Galera Therapeutics Balance Sheet
0.000.00%
- $1.81m
- $144.57m
Annual balance sheet for Galera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 72.8 | 71.2 | 31.6 | 18.3 | 8.29 |
Net Total Receivables | — | — | — | — | 0.635 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 77.9 | 77.4 | 38.5 | 21.6 | 10 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.55 | 0.823 | 0.481 | 1.28 | 0 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 84.1 | 83.3 | 44 | 26.1 | 10.1 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 14 | 12.9 | 13.4 | 4.96 | 1.67 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 78 | 141 | 153 | 157 | 154 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 6.12 | -58 | -109 | -131 | -144 |
Total Liabilities & Shareholders' Equity | 84.1 | 83.3 | 44 | 26.1 | 10.1 |
Total Common Shares Outstanding |